Oregon Supplement: Supporting Sustainable Positive Interactions in the Child Welfare System: The R3 Supervisor Strategy

July 22, 2022 updated by: Oregon Social Learning Center
This administrative supplement capitalized on the preliminary positive outcomes from the primary parent grant award (R01DA040416), and lessons learned from the implementation of the R3 Supervisor Strategy (R3) throughout the participating four regions (12 counties) in Tennessee. This project aimed to pilot the implementation of R3 with a new sample, a cohort of counties in Oregon particularly affected by the current opioid epidemic, for potential scale-up.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Oregon currently is experiencing a crisis within its Child Welfare System (CWS), with combined challenges within the workforce and departmental support, and a staggering rise in referrals for parental substance abuse. The R3 Supervisor Strategy (R3) provides training, consultation, and fidelity-monitoring to supervisors in the CWS, who are centrally positioned between caseworkers (who have daily interactions with CWS-involved families) and leadership (who make decisions that affect the organization in which families receive services). Supervisors are trained to implement key reinforcement strategies that make up the three Rs including reinforcement of (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement. R3 is relatively easy to learn and sustain and has demonstrated promise in improving CWS outcomes in the parent grant award (R01DA040416). Because many of the counties most impacted by the opioid crisis are rural and under-resourced, an approach like R3 provides the opportunity to introduce evidence-based strategies to these regions where it otherwise is not feasible to adopt more intensive services. This study utilized the same Hybrid Type II design as its parent grant in which supervisors and caseworkers from two Oregon counties particularly affected by the substance abuse crisis were recruited to to provide a pilot assessment of the effectiveness of R3 with an emphasis on referrals for opioid and methamphetamine use (Aim 1). In doing so, the study also sought to modify the R3 training materials to emphasize examples of working with families referred for parental substance abuse (Aim 2) and replicate the preliminary findings from the parent grant, providing pilot data for a larger state scale-up of R3. This administrative supplement allowed an initial assessment to identify if R3's strategies are profound enough to impact the most challenging systems, faced with the most challenging public health crisis presented currently-the impact of the opioid epidemic on families.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
404

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Oregon
      • Eugene, Oregon, United States, 97401
        • Oregon Social Learning Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Study participants include casework supervisors in the child welfare system (CWS) from two counties most heavily impacted by the opioid and methamphetamine crisis (Lane and Douglas county).

Description

Inclusion Criteria:

  • Oregon Child welfare workforce employee in a participating county.

Exclusion Criteria:

- Contract Workers

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort

Group / Cohort

A group or subgroup of participants in an observational study that is assessed for biomedical or health outcomes.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Oregon County 1
First cohort to be trained and monitored with coaching in the R3 model.
Behavioral: R3
Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.
Oregon County 2
Second cohort to be trained and monitored with coaching in the R3 model.
Behavioral: R3
Training, consultation, and fidelity-monitoring to supervisors in the child welfare system to reinforce (1) effort, (2) relationships and roles, and (3) small steps toward goal achievement.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Mean Changes in Organizational Support of Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in overall organizational support of evidence-based practices (i.e., R3) as measured through the Implementation Citizenship Behavior Scale's (ICBS) total score. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Assistance Implementing Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization helping others implement Evidence-Based Practices (i.e., R3) as measured through the Implementation Citizenship Behavior Scale's (ICBS) "Helping Other's" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organization Keeping Others Informed of Evidence-Based Practices Changes and Needs from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization keeping others informed of changes and needs in evidence-based practices (i.e., R3) as measured through the Implementation Citizenship Behavior Scale's (ICBS) "Keeping Informed" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organizational Climate for Implementing Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in organizational climate for implementing evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) total score. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organizational Focus on Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in organizational focus on evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) "Focus on Evidence-Based Practices" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organization's Educational Support for Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization's educational support for evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) "Educational Support for Evidence-Based Practices" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Recognition for Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization's recognition for evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) "Recognition for Evidence-Based Practices" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Rewards for Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization's rewards for using evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) "Rewards for Evidence-Based Practices" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organization's Selection for Evidence-Based Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization's selection for evidence-based practices (i.e., R3) as measured by the Implementation Climate Scale's (ICS) "Selection for Evidence-Based Practices" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in the Organization's Selection for Openness to New Practices from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in the organization's selection for openness to implement new practices as measured by the Implementation Climate Scale's (ICS) "Selection for Openness" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Self-Reported Leadership Abilities for Implementation from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in supervisors' self-reported leadership abilities for implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) total score. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Self-Reported Ability to Provide Proactive Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in supervisors' self-reported ability to provide proactive leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Proactive Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Self-Reported Ability to Provide Knowledgeable Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in supervisors' self-reported ability to provide knowledgeable leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Knowledgeable Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Self-Reported Ability to Provide Supportive Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in supervisors' self-reported ability to provide supportive leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Supportive Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Self-Reported Ability to Provide Perseverant Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in supervisors' self-reported ability to provide perseverant leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Perseverant Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Leadership Ability for Implementation from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their supervisors' leadership abilities for implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) total score. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Ability to Provide Proactive Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their supervisors' ability to provide proactive leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Proactive Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Ability to Provide Knowledgeable Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their supervisors' ability to provide knowledgeable leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Knowledgeable Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Ability to Provide Supportive Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their supervisors' ability to provide supportive leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Supportive Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Supervisors' Ability to Provide Perseverant Leadership from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their supervisors' ability to provide perseverant leadership when implementing evidence-based practices (i.e., R3) as measured by the Implementation Leadership Scale's (ILS) "Perseverant Leadership" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Commitment to Implementing Changes from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their organization's commitment to implementing changes as measured by the Organizational Readiness for Implementing Change's (ORIC) "Change Commitment" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Effectiveness in Implementing Changes from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their organization's effectiveness in implementing changes as measured by the Organizational Readiness for Implementing Change's (ORIC) "Change Efficacy" subscale. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline
Mean Changes in Organizational Readiness to Implement Changes from Baseline to 18-Months Post-Baseline
Time Frame: Baseline to 18-months Post-Baseline
Changes in staff perceptions of their organization's overall readiness in implementing changes as measured by the Organizational Readiness for Implementing Change's (ORIC) total score. Measured at Baseline, 6-, 12-, and 18-months Post-Baseline.
Baseline to 18-months Post-Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Oregon Social Learning Center

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
National Institute on Drug Abuse (NIDA)

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
April 8, 2019

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 16, 2021

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 16, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 22, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 22, 2022

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 27, 2022

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 27, 2022

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 22, 2022

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2022

More Information

Terms related to this study

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • R01DA040416-S1
  • R01DA040416 (NIH)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings